

FOI – 2075

17th January 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs:

- **Amphotericin B (Ambisome)**
- **Caspofungin (Cancidas)**
- **Isavuconazole (Cresemba)**
- **Posaconazole (Noxafil)**
- **Voriconazole (VFEND)**

We do not record patient specific details for items issued to inpatients. Our trust can only provide data based on discharges.

- Amphotericin B (Ambisome) - Unknown
- Caspofungin (Cancidas) - Unknown
- Isavuconazole (Cresemba) - Unknown
- Posaconazole (Noxafil) – 10 patients
- Voriconazole (VFEND) – 8 patients

Q2a. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillosis (ICD10 code: B44)?

Number of finished consultant episodes and daycases with a diagnosis of Aspergillosis between 01.10.2022 – 30/09/2023

<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all

information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figure from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2b. Of the above patients diagnosed with Aspergillosis in the last 12 months, how many patients were treated with the following drugs:

- **Amphotericin B (Ambisome)**
- **Caspofungin (Cancidas)**
- **Isavuconazole (Cresemba)**
- **Posaconazole (Noxafil)**
- **Voriconazole (VFEND)**

We do not record patient specific details for items issued to inpatients. Our trust can only provide data based on discharges.

Q3a. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?

Number of finished consultant episodes and daycases with a diagnosis of Mucormycosis with date of discharge between 01.10.2022 – 30.09.2023

<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figure from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q3b. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs:

- **Amphotericin B (Ambisome)**
- **Isavuconazole (Cresemba)**
- **Posaconazole (Noxafil)**

We do not record patient specific details for items issued to inpatients. Our trust can only provide data based on discharges.

Email: foi.team@southerntrust.hscni.net